Panagiotis Giamougiannis

Panagiotis Giamougiannis

Auto-generated profile, based on publicly available information

Panagiotis Giamougiannis

Department of Obstetrics and Gynaecology Lancashire Teaching Hospitals NHS Foundation Trust Preston UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2021 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
PGPanagiotis Giamougiannis
Panagiotis Giamougiannis
PMPierre L Martin-Hirsch
Pierre L Martin-Hirsch
FMFrancis L Martin
Francis L Martin
MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.

22 July 2021 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
PGPanagiotis Giamougiannis
Panagiotis Giamougiannis
RSRaissa V. O. Silva
Raissa V. O. Silva
DFDaniel Lucas Dantas de Freitas
Daniel Lucas Dantas de Freitas
Kássio LimaKássio Lima
Kássio Lima
AAAntonios Anagnostopoulos
Antonios Anagnostopoulos
FMFrancis L Martin
Francis L Martin

13 July 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
CMCamilo L.M. Morais
Camilo L.M. Morais
PGPanagiotis Giamougiannis
Panagiotis Giamougiannis
RGRita Grabowska
Rita Grabowska
NWNicholas J. Wood
Nicholas J. Wood
PMPierre L. Martin-Hirsch
Pierre L. Martin-Hirsch
FMFrancis L Martin
Francis L Martin
Raman hyperspectral imaging is a powerful technique that provides both chemical and spatial information of a sample matrix being studied. The generated data are composed of three-dimensional (3D) arrays containing the spatial information across the x- and y-axis, and the spectral information in the z-axis. Unfolding procedures are commonly employed to analyze this type of data in a multivariate fashion, where the spatial dimension is reshaped and the spectral data fits into a two-dimensional (2D) structure and, thereafter, common first-order chemometric algorithms are applied to process the data. There are only a few algorithms capable of working with the full 3D array. Herein, we propose new algorithms for 3D discriminant analysis of hyperspectral images based on a three-dimensional principal component analysis linear discriminant analysis (3D-PCA-LDA) and a three-dimensional discriminant analysis quadratic discriminant analysis (3D-PCA-QDA) approach. The analysis was performed in order to discriminate simulated and real-world data, comprising benign controls and ovarian cancer samples based on Raman hyperspectral imaging, in which 3D-PCA-LDA and 3D-PCA-QDA achieved far superior performance than classical algorithms using unfolding procedures (PCA-LDA, PCA-QDA, partial lest squares discriminant analysis [PLS-DA], and support vector machines [SVM]), where the classification accuracies improved from 66% to 83% (simulated data) and from 50% to 100% (real-world dataset) after employing the 3D techniques. 3D-PCA-LDA and 3D-PCA-QDA are new approaches for discriminant analysis of hyperspectral images multisets to provide faster and superior classification performance than traditional techniques.

24 May 2021 in European Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
HDHannah Donkers
Hannah Donkers
JMJohn McGrane
John McGrane
AEAntonio Eleuteri
Antonio Eleuteri
PGPanagiotis Giamougiannis
Panagiotis Giamougiannis
Ruud BekkersRuud Bekkers
Ruud Bekkers
KGKhadra Galaal
Khadra Galaal
Objectives To assess the association between risk factors, including socioeconomic deprivation, and mortality, recurrence and chemo- or radiation toxicity in cervical cancer patients. Methods Retrospective study of cervical cancer patients diagnosed between January 2007 and July 2018. Patient characteristics and mortality data, including recurrence, were assessed, together with socioeconomic deprivation measures evaluated using the English Indices of Multiple Deprivation. Markov multi-state models were used to model mortality and recurrence, and logistic regression models were used to model chemo- or radiation toxicity. Results Included were 243 women with a median age of 49 years. A total of 57 patients died (23%), of which 41 due to cervical cancer, and 21 (9%) had recurrent disease. Hazard ratios (HR) showed no evidence of association between socioeconomic deprivation and cancer-specific hazard of mortality from diagnosis or recurrence, hazard of mortality due to other causes or hazard of cancer recurrence. Furthermore, there was no evidence of association between socioeconomic deprivation and chemo- or radiation toxicity (bowel, bladder or vaginal stenosis). Conclusions No associations were found between socioeconomic deprivation and cancer mortality or recurrence in cervical cancer patients in the population of Cornwall. In addition, no association was found between socioeconomic deprivation and chemo- or radiation toxicity.